Program
NTI164
A development code. Also written as “FEN164”.
Its studies are mostly in Autism Spectrum Disorder · Rett Syndrome · Autistic Disorder, led by Fenix Innovation Group.
Furthest: phase 3, since Nov 15, 20227 company-led studies, 2 open or runningNext primary completion: Oct 1, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fenix Innovation Group | 72 open or running | phase 3since Nov 15, 2022 | Apr 4, 2022 | Oct 1, 2028phase 3 · NCT07257978 |
Also a collaborator on its studies: neurotech-international-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 4, 2022First study: phase 2 study in Autism Spectrum DisorderFirst studyNCT05516407 · 18 enrolled · Australia
- Nov 15, 2022Phase 3 study in Autism Spectrum DisorderNCT05626959 · 54 enrolled · Australia
- Sep 11, 20242 phase 2 studiesNCT06621888, NCT06621043
- Nov 26, 2024Phase 1 study in Marijuana AbuseNCT06713447 · 12 enrolled · Australia
- Jul 18, 2025Phase 3 study in Rett SyndromeNCT07257978 · 40 planned · Australia
- Nov 17, 2025Phase 3 study in Autistic DisorderNCT07257939 · 200 planned · Australia
Ahead
- Oct 1, 2028Primary completion: phase 3 study in Rett SyndromeNCT07257978
- Jul 1, 2029Primary completion: phase 3 study in Autistic DisorderNCT07257939
TargetBeta
GCNT2 →read by rule
“NTI164 is a potently anti-inflammatory oil which has demonstrated efficacy in reducing symptoms in several paediatric neurological conditions, including RTT (Phase I/II), autism spectrum disorder (ASD), and paediatric acute-onset neuropsychicatric syndrome (PANS).”study text, by rule · the study
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07257939Autistic Disorder · Australia | 3 | Not yet recruiting | Jul 1, 2029 | 200 |
| NCT07257978Rett Syndrome · Australia | 3 | Not yet recruiting | Oct 1, 2028 | 40 |
| NCT06713447Marijuana Abuse · Australia | 1 | Completed | Jun 1, 2025 | 12 |
| NCT06621888Pediatric acute-onset neuropsychiatric syndrome · Australia | 2 | Completed | Dec 1, 2025 | 18 |
| NCT06621043Rett Syndrome · Australia | 2 | Completed | Dec 1, 2025 | 14 |
| NCT05626959Autism Spectrum Disorder · Australia | 3 | Completed | Mar 1, 2024 | 54 |
| NCT05516407Autism Spectrum Disorder · Australia | 2 | Completed | Sep 1, 2022 | 18 |
How it is read
Names in the registry
- “NTI164”, 6 entries
- “FEN164”, 1 entry
Codes read as this program: NTI164, FEN164.
Conditions, from the studies’ own filings
- Autism Spectrum Disorder, 2 studies
- Rett Syndrome, 2 studies
- Autistic Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.